Celldex Therapeutics (CLDX) Financials

$22.08 -0.30 (-1.34%)

Closing price 08/29/2025 04:00 PM Eastern

Extended Trading

$22.08 0.00 (0.00%)

As of 08/29/2025 06:08 PM Eastern

Annual Income Statements for Celldex Therapeutics

This table shows Celldex Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2014	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	-118	-127	-129	-93	-151	-51	-60	-71	-112	-141	-158
Consolidated Net Income / (Loss)	-118	-127	-129	-93	-151	-51	-60	-71	-112	-141	-158
Net Income / (Loss) Continuing Operations	-118	-127	-129	-93	-151	-51	-60	-71	-112	-141	-158
Total Pre-Tax Income	-118	-127	-129	-117	-152	-51	-61	-71	-112	-141	-158
Total Operating Income	-122	-130	-133	-122	-156	-55	-63	-71	-115	-155	-195
Total Gross Profit	3.59	5.48	6.79	13	9.54	3.57	7.42	4.65	2.36	6.88	7.02
Total Revenue	3.59	5.48	6.79	13	9.54	3.57	7.42	4.65	2.36	6.88	7.02
Operating Revenue	3.59	5.48	6.79	13	9.54	3.57	7.42	4.65	2.36	6.88	7.02
Total Cost of Revenue	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Operating Expenses	126	135	140	134	166	59	71	76	118	161	202
Selling, General & Admin Expense	21	34	36	25	19	15	14	20	27	31	39
Research & Development Expense	104	100	103	96	66	43	43	53	82	118	164
Other Operating Expenses / (Income)	-	-	-	-0.80	-30	-1.29	-4.22	-1.41	-6.86	0.00	0.00
Other Special Charges / (Income)	-	-	-	-	-	-	0.00	0.00	15	13	0.00
Total Other Income / (Expense), net	4.35	2.34	4.39	4.21	4.49	4.15	2.41	0.51	2.91	13	37
Interest & Investment Income	4.35	2.34	4.39	4.21	4.49	4.15	2.41	0.51	2.91	13	37
Basic Earnings per Share	($1.32)	($1.31)	($18.99)	($10.86)	($14.48)	($3.51)	($2.02)	($1.64)	($2.40)	($2.92)	($2.45)
Weighted Average Basic Shares Outstanding	89.40M	97.05M	6.77M	8.57M	10.44M	14.51M	29.64M	42.87M	46.89M	48.45M	64.40M
Diluted Earnings per Share	($1.32)	($1.31)	($18.99)	($10.86)	($14.48)	($3.51)	($2.02)	($1.64)	($2.40)	($2.92)	($2.45)
Weighted Average Diluted Shares Outstanding	89.40M	97.05M	6.77M	8.57M	10.44M	14.51M	29.64M	42.87M	46.89M	48.45M	64.40M
Weighted Average Basic & Diluted Shares Outstanding	89.40M	97.05M	6.77M	8.57M	10.44M	14.51M	29.64M	46.74M	47.21M	55.90M	66.38M

This table shows Celldex Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025
Net Income / (Loss) Attributable to Common Shareholders	-27	-26	-29	-31	-38	-43	-33	-36	-42	-47	-54
Consolidated Net Income / (Loss)	-27	-26	-29	-31	-38	-43	-33	-36	-42	-47	-54
Net Income / (Loss) Continuing Operations	-27	-26	-29	-31	-38	-43	-33	-36	-42	-47	-54
Total Pre-Tax Income	-27	-86	0.00	0.00	0.00	-141	-33	0.00	0.00	-158	-54
Total Operating Income	-28	-28	-32	-33	-41	-48	-41	-46	-52	-56	-63
Total Gross Profit	0.41	1.61	0.97	0.27	1.52	4.13	0.16	2.50	3.19	1.18	0.70
Total Revenue	0.41	1.61	0.97	0.27	1.52	4.13	0.16	2.50	3.19	1.18	0.70
Operating Revenue	0.41	1.61	0.97	0.27	1.52	4.13	0.16	2.50	3.19	1.18	0.70
Total Cost of Revenue	0.00	-	0.00	0.00	0.00	-	0.00	0.00	0.00	-	0.00
Total Operating Expenses	28	29	33	33	43	52	41	49	55	57	63
Selling, General & Admin Expense	6.53	6.60	6.64	7.22	8.22	8.83	9.10	9.13	10	10	11
Research & Development Expense	22	23	27	26	35	30	32	40	45	47	53
Total Other Income / (Expense), net	0.91	1.40	3.11	2.70	2.98	4.32	7.80	10	10	8.94	8.94
Interest & Investment Income	0.91	1.40	3.11	2.70	2.98	4.32	7.80	10	10	8.94	8.94
Basic Earnings per Share	($0.57)	($0.57)	($0.62)	($0.65)	($0.81)	($0.84)	($0.56)	($0.54)	($0.64)	($0.71)	($0.81)
Weighted Average Basic Shares Outstanding	46.92M	46.89M	47.21M	47.25M	47.26M	48.45M	58.87M	66.02M	66.29M	64.40M	66.38M
Diluted Earnings per Share	($0.57)	($0.57)	($0.62)	($0.65)	($0.81)	($0.84)	($0.56)	($0.54)	($0.64)	($0.71)	($0.81)
Weighted Average Diluted Shares Outstanding	46.92M	46.89M	47.21M	47.25M	47.26M	48.45M	58.87M	66.02M	66.29M	64.40M	66.38M
Weighted Average Basic & Diluted Shares Outstanding	47.10M	47.21M	47.25M	47.26M	47.26M	55.90M	65.91M	66.29M	66.34M	66.38M	66.39M

This table details how cash moves in and out of Celldex Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2014	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Net Change in Cash & Equivalents	-141	44	-30	-2.17	-16	-13	33	-4.69	-9.71	5.39	-6.46
Net Cash From Operating Activities	-102	-99	-113	-100	-75	-46	-40	-61	-104	-107	-158
Net Cash From Continuing Operating Activities	-102	-99	-113	-100	-75	-46	-40	-61	-104	-107	-158
Net Income / (Loss) Continuing Operations	-118	-127	-129	-93	-151	-51	-60	-71	-112	-141	-158
Consolidated Net Income / (Loss)	-118	-127	-129	-93	-151	-51	-60	-71	-112	-141	-158
Depreciation Expense	2.39	3.00	3.10	4.41	3.58	4.86	3.93	3.07	2.90	3.01	3.18
Amortization Expense	1.18	1.65	3.56	1.19	-0.82	-1.14	-0.73	-3.21	0.84	-6.22	-16
Non-Cash Adjustments To Reconcile Net Income	6.85	13	15	0.98	89	5.07	21	12	16	24	34
Changes in Operating Assets and Liabilities, net	6.13	11	-6.56	-13	-15	-4.32	-4.52	-2.46	-11	13	-22
Net Cash From Investing Activities	-41	-50	69	46	30	17	-98	-216	90	-106	-290
Net Cash From Continuing Investing Activities	-41	-50	69	46	30	17	-98	-216	90	-106	-290
Purchase of Property, Plant & Equipment	-1.93	-4.88	-2.75	-1.79	-0.81	-0.73	-1.55	-1.25	-1.83	-1.82	-1.92
Purchase of Investments	-148	-206	-176	-171	-171	-95	-220	-390	-189	-425	-790
Sale of Property, Plant & Equipment	-	-	-	-	0.34	0.02	0.06	0.03	0.07	0.00	0.00
Sale and/or Maturity of Investments	109	161	243	219	201	113	124	175	281	321	502
Other Investing Activities, net	-	-	-	-	-	-	-	-0.29	-0.11	-0.08	-0.03
Net Cash From Financing Activities	1.17	193	14	51	29	16	171	272	4.08	218	441
Net Cash From Continuing Financing Activities	1.17	193	14	51	29	16	171	272	4.08	218	441
Issuance of Common Equity	1.17	193	14	51	29	16	171	272	4.08	218	441

This table details how cash moves in and out of Celldex Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025
Net Change in Cash & Equivalents	-9.82	11	25	-26	-7.09	14	80	-72	-6.34	-8.04	-11
Net Cash From Operating Activities	-35	-22	-29	-27	-19	-33	-41	-29	-55	-32	-54
Net Cash From Continuing Operating Activities	-35	-22	-29	-27	-19	-33	-41	-29	-55	-32	-54
Net Income / (Loss) Continuing Operations	-27	-26	-29	-31	-38	-43	-33	-36	-42	-47	-54
Consolidated Net Income / (Loss)	-27	-26	-29	-31	-38	-43	-33	-36	-42	-47	-54
Depreciation Expense	0.67	0.67	0.73	0.76	0.77	0.76	0.78	0.80	0.79	0.82	0.87
Amortization Expense	0.06	-0.52	-1.26	-1.16	-1.63	-2.18	-3.31	-4.74	-4.33	-3.36	-2.27
Non-Cash Adjustments To Reconcile Net Income	-11	4.51	4.34	5.22	7.12	7.21	7.21	7.64	9.62	9.78	9.32
Changes in Operating Assets and Liabilities, net	1.42	0.07	-3.02	-1.51	13	4.98	-13	2.82	-19	7.38	-8.50
Net Cash From Investing Activities	23	31	53	1.16	12	-171	-315	-47	48	24	43
Net Cash From Continuing Investing Activities	23	31	52	1.25	11	-171	-315	-47	48	24	43
Purchase of Property, Plant & Equipment	-0.35	-0.24	-0.59	-0.41	-0.16	-0.67	-0.34	-0.27	-0.55	-0.76	-0.27
Purchase of Investments	-63	-56	-74	-82	-28	-241	-392	-169	-100	-129	-152
Sale and/or Maturity of Investments	86	88	127	83	40	71	77	122	148	154	195
Net Cash From Financing Activities	2.31	1.40	0.69	0.13	0.26	217	436	3.71	1.24	0.39	0.20
Net Cash From Continuing Financing Activities	2.31	1.40	0.69	0.13	0.26	217	436	3.71	1.24	0.39	0.20
Issuance of Common Equity	2.31	1.40	0.69	0.13	0.26	217	436	3.71	1.24	0.39	0.20

This table presents Celldex Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2014	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Total Assets	248	338	383	316	156	123	236	445	353	466	792
Total Current Assets	205	295	196	145	99	67	198	411	318	432	747
Cash & Equivalents	28	72	42	40	24	11	44	39	29	35	28
Short-Term Investments	173	218	147	99	70	53	151	369	276	389	697
Accounts Receivable	0.43	0.97	1.78	1.88	3.16	1.02	1.80	0.17	0.35	2.63	0.70
Prepaid Expenses	3.52	4.08	4.01	3.45	1.90	1.30	1.62	2.42	12	5.47	21
Plant, Property, & Equipment, net	11	11	13	10	6.11	4.03	3.82	3.55	3.75	4.06	4.35
Total Noncurrent Assets	32	31	175	160	51	52	34	30	31	30	41
Intangible Assets	22	21	81	68	49	49	31	27	27	27	27
Other Noncurrent Operating Assets	1.72	1.43	2.13	1.93	1.93	3.51	3.49	3.07	4.11	2.68	14
Total Liabilities & Shareholders' Equity	248	338	383	316	156	123	236	445	353	466	792
Total Liabilities	36	47	118	79	32	29	26	25	27	36	45
Total Current Liabilities	24	30	35	28	13	12	14	17	19	31	40
Accounts Payable	2.60	1.51	1.74	1.72	1.07	1.17	1.05	1.23	3.34	3.49	3.27
Accrued Expenses	19	24	29	19	7.01	6.50	8.46	12	13	22	34
Other Current Liabilities	2.59	4.42	4.83	6.57	4.53	3.97	4.70	3.30	2.44	5.60	2.39
Total Noncurrent Liabilities	12	17	83	52	19	17	12	8.65	7.92	5.33	5.83
Other Noncurrent Operating Liabilities	12	17	83	52	19	17	12	8.65	7.92	5.33	5.83
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	212	290	265	236	124	94	209	419	326	429	747
Total Preferred & Common Equity	212	290	265	236	124	94	209	419	326	429	747
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	-	0.00	0.00	0.00	0.00
Total Common Equity	212	290	265	236	124	94	209	419	326	429	747
Common Stock	673	879	982	1,046	1,084	1,105	1,280	1,561	1,581	1,823	2,299
Retained Earnings	-464	-591	-719	-813	-962	-1,013	-1,073	-1,144	-1,256	-1,397	-1,555
Accumulated Other Comprehensive Income / (Loss)	2.59	2.31	2.54	2.56	2.58	2.62	2.59	1.89	1.26	3.31	3.31

This table presents Celldex Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q2 2022	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024	Q1 2025
Period end date	6/30/2022	9/30/2022	3/31/2023	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024	3/31/2025
Total Assets	403	369	325	299	280	869	846	823	739
Total Current Assets	368	335	290	265	246	835	812	779	694
Cash & Equivalents	28	19	54	28	21	115	43	36	17
Short-Term Investments	328	305	224	224	214	709	760	720	656
Accounts Receivable	0.10	0.19	1.31	0.12	0.25	2.67	1.53	0.85	1.06
Prepaid Expenses	11	11	9.90	12	10	8.81	8.12	22	19
Plant, Property, & Equipment, net	3.74	3.75	4.00	3.94	4.16	4.06	3.86	4.23	4.60
Total Noncurrent Assets	31	31	31	31	30	29	30	40	41
Intangible Assets	27	27	27	27	27	27	27	27	27
Other Noncurrent Operating Assets	4.05	3.68	3.74	3.36	2.97	2.27	2.56	13	14
Total Liabilities & Shareholders' Equity	403	369	325	299	280	869	846	823	739
Total Liabilities	38	24	22	22	34	30	32	37	36
Total Current Liabilities	30	16	15	16	28	26	28	32	32
Accounts Payable	0.90	2.27	3.37	0.88	3.59	3.23	3.80	1.11	3.41
Accrued Expenses	11	11	9.37	12	18	18	19	28	25
Other Current Liabilities	18	2.59	2.47	2.51	5.78	5.52	5.26	2.78	3.15
Total Noncurrent Liabilities	7.92	7.52	6.56	6.13	5.70	3.94	4.27	5.18	4.47
Other Noncurrent Operating Liabilities	7.92	7.52	6.56	6.13	5.70	3.94	4.27	5.18	4.47
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	365	345	303	278	247	839	814	786	703
Total Preferred & Common Equity	365	345	303	278	247	839	814	786	703
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	365	345	303	278	247	839	814	786	703
Common Stock	1,568	1,575	1,586	1,591	1,599	2,267	2,278	2,289	2,308
Retained Earnings	-1,203	-1,229	-1,285	-1,316	-1,354	-1,430	-1,466	-1,508	-1,609
Accumulated Other Comprehensive Income / (Loss)	-0.42	-0.11	2.12	2.07	2.14	2.24	1.78	5.29	3.57

This table displays calculated financial ratios and metrics derived from Celldex Therapeutics' official financial filings.

Metric	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2014	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	-12.77%	52.82%	23.83%	87.78%	-25.15%	-62.54%	107.61%	-37.30%	-49.32%	192.02%	1.99%
EBITDA Growth	-49.01%	-5.07%	-1.10%	8.18%	-32.57%	66.61%	-17.23%	-18.67%	-56.19%	-41.49%	-31.63%
EBIT Growth	-50.33%	-5.81%	-2.61%	8.57%	-28.73%	64.82%	-15.12%	-12.45%	-61.75%	-34.11%	-26.23%
NOPAT Growth	-50.33%	-5.81%	-2.61%	8.57%	-28.73%	64.82%	-15.12%	-12.45%	-61.75%	-34.11%	-26.23%
Net Income Growth	-44.79%	-7.72%	-1.05%	27.62%	-62.51%	66.35%	-17.50%	-17.95%	-59.30%	-25.91%	-11.62%
EPS Growth	-29.41%	0.76%	-1.05%	27.62%	-62.51%	75.76%	42.45%	18.81%	-46.34%	-21.67%	16.10%
Operating Cash Flow Growth	-50.05%	2.61%	-14.31%	11.59%	24.71%	38.31%	12.95%	-50.75%	-70.31%	-3.43%	-47.06%
Free Cash Flow Firm Growth	-56.91%	-0.97%	-109.87%	36.87%	59.94%	10.50%	22.26%	-55.74%	-96.46%	-2.00%	-65.09%
Invested Capital Growth	-36.85%	-97.97%	34,925.46%	28.14%	-69.01%	-1.32%	-49.62%	-24.83%	89.31%	-73.78%	289.81%
Revenue Q/Q Growth	31.40%	6.06%	1.25%	14.17%	-15.05%	-19.74%	64.15%	-42.61%	118.85%	57.69%	-29.63%
EBITDA Q/Q Growth	-7.96%	-0.94%	-0.43%	6.56%	7.26%	-4.44%	-20.83%	6.51%	-8.12%	-15.62%	-4.81%
EBIT Q/Q Growth	-8.83%	-1.08%	-1.08%	7.13%	7.89%	-1.60%	-22.87%	5.87%	-7.01%	-14.65%	-4.50%
NOPAT Q/Q Growth	-8.83%	-1.08%	-1.08%	7.13%	7.89%	-1.60%	-22.87%	5.87%	-7.01%	-14.65%	-4.50%
Net Income Q/Q Growth	-9.01%	-0.68%	0.29%	23.43%	-3.82%	-2.10%	-23.70%	2.42%	-5.98%	-13.50%	-2.46%
EPS Q/Q Growth	-8.20%	2.24%	0.29%	23.43%	-3.82%	-7.67%	-64.23%	-3.14%	-6.19%	-10.19%	5.04%
Operating Cash Flow Q/Q Growth	-7.70%	7.89%	-6.20%	0.82%	5.16%	8.71%	12.53%	-18.05%	-7.50%	-11.16%	0.04%
Free Cash Flow Firm Q/Q Growth	-7.61%	9.22%	-83.37%	31.99%	32.14%	13.07%	22.03%	-27.45%	-8.35%	-10.40%	-2.34%
Invested Capital Q/Q Growth	-30.58%	-98.46%	446.48%	23.30%	33.41%	4.15%	-50.84%	-17.60%	-3.16%	-50.99%	-27.36%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
EBITDA Margin	-3,314.61%	-2,279.05%	-1,860.60%	-909.73%	-1,611.27%	-1,436.13%	-810.92%	-1,534.81%	-4,730.34%	-2,291.97%	-2,957.98%
Operating Margin	-3,414.11%	-2,363.89%	-1,958.68%	-953.68%	-1,640.13%	-1,540.19%	-854.06%	-1,531.78%	-4,889.01%	-2,245.27%	-2,778.89%
EBIT Margin	-3,414.11%	-2,363.89%	-1,958.68%	-953.68%	-1,640.13%	-1,540.19%	-854.06%	-1,531.78%	-4,889.01%	-2,245.27%	-2,778.89%
Profit (Net Income) Margin	-3,292.81%	-2,321.11%	-1,894.05%	-730.06%	-1,585.07%	-1,423.96%	-805.88%	-1,516.04%	-4,765.59%	-2,054.76%	-2,248.76%
Tax Burden Percent	100.00%	100.00%	100.00%	79.30%	99.50%	100.00%	98.09%	99.68%	100.00%	100.00%	100.00%
Interest Burden Percent	96.45%	98.19%	96.70%	96.53%	97.13%	92.45%	96.20%	99.29%	97.48%	91.51%	80.92%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-624.89%	-1,674.12%	-245.26%	-98.58%	-172.48%	-129.09%	-198.97%	-381.26%	-496.73%	-806.56%	-1,000.51%
ROIC Less NNEP Spread (ROIC-NNEP)	-612.05%	-1,659.24%	-230.46%	-93.74%	-136.77%	-113.49%	-187.04%	-374.41%	-487.85%	-797.43%	-996.80%
Return on Net Nonoperating Assets (RNNOA)	580.46%	1,623.42%	198.99%	61.50%	88.59%	82.43%	159.56%	358.83%	466.60%	769.11%	973.67%
Return on Equity (ROE)	-44.44%	-50.70%	-46.27%	-37.08%	-83.89%	-46.66%	-39.41%	-22.43%	-30.13%	-37.45%	-26.84%
Cash Return on Invested Capital (CROIC)	-579.72%	-1,482.10%	-444.12%	-123.24%	-67.10%	-127.77%	-132.98%	-352.90%	-558.47%	-689.66%	-1,118.85%
Operating Return on Assets (OROA)	-41.15%	-44.24%	-36.87%	-34.77%	-66.37%	-39.49%	-35.32%	-20.94%	-28.90%	-37.77%	-31.01%
Return on Assets (ROA)	-39.68%	-43.44%	-35.66%	-26.62%	-64.14%	-36.51%	-33.32%	-20.72%	-28.17%	-34.56%	-25.10%
Return on Common Equity (ROCE)	-44.44%	-50.70%	-46.27%	-37.08%	-83.89%	-46.66%	-39.41%	-22.43%	-30.13%	-37.45%	-26.84%
Return on Equity Simple (ROE_SIMPLE)	-55.79%	-43.85%	-48.42%	-39.36%	-121.86%	-54.11%	-28.55%	-16.81%	-34.43%	-32.95%	-21.13%
Net Operating Profit after Tax (NOPAT)	-86	-91	-93	-85	-110	-39	-44	-50	-81	-108	-137
NOPAT Margin	-2,389.88%	-1,654.72%	-1,371.08%	-667.57%	-1,148.09%	-1,078.13%	-597.84%	-1,072.24%	-3,422.31%	-1,571.69%	-1,945.22%
Net Nonoperating Expense Percent (NNEP)	-12.85%	-14.88%	-14.80%	-4.84%	-35.71%	-15.60%	-11.93%	-6.85%	-8.88%	-9.13%	-3.71%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-	-	-	-24.73%	-25.21%	-18.28%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	575.07%	617.46%	530.19%	196.21%	202.02%	431.74%	194.88%	440.51%	1,153.80%	449.14%	549.12%
R&D to Revenue	2,910.79%	1,827.94%	1,513.79%	754.70%	696.68%	1,194.29%	573.39%	1,146.23%	3,489.94%	1,714.53%	2,329.77%
Operating Expenses to Revenue	3,514.11%	2,463.89%	2,058.68%	1,053.68%	1,740.13%	1,640.19%	954.06%	1,631.78%	4,989.01%	2,345.27%	2,878.89%
Earnings before Interest and Taxes (EBIT)	-122	-130	-133	-122	-156	-55	-63	-71	-115	-155	-195
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-119	-125	-126	-116	-154	-51	-60	-71	-111	-158	-208
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	7.72	5.33	1.35	1.63	0.28	0.38	3.31	4.30	6.44	4.37	2.24
Price to Tangible Book Value (P/TBV)	9.04	5.94	3.86	4.96	0.45	0.79	3.88	4.60	7.02	4.66	2.33
Price to Revenue (P/Rev)	455.94	282.26	52.82	30.31	3.58	10.07	93.45	387.68	890.64	272.34	238.82
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	135.06	5,818.87	2.23	2.55	0.00	0.00	33.40	124.25	84.43	260.34	43.79
Enterprise Value to Revenue (EV/Rev)	399.88	229.36	24.85	19.37	0.00	0.00	67.24	299.90	761.26	210.79	135.50
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-0.95	-0.98	-0.86	-0.66	-0.65	-0.73	-0.85	-0.96	-0.96	-0.96	-0.98
Leverage Ratio	1.12	1.17	1.30	1.39	1.31	1.28	1.18	1.08	1.07	1.08	1.07
Compound Leverage Factor	1.08	1.15	1.25	1.34	1.27	1.18	1.14	1.07	1.04	0.99	0.87
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	23.63	16.79	-1.43	-1.47	-10.59	-11.70	9.42	39.91	42.44	26.60	19.71
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	8.37	9.75	5.55	5.22	7.86	5.73	13.93	24.86	17.07	13.87	18.91
Quick Ratio	8.23	9.62	5.44	5.09	7.71	5.62	13.81	24.71	16.41	13.69	18.38
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-80	-80	-168	-106	-43	-38	-30	-46	-91	-93	-153
Operating Cash Flow to CapEx	-5,263.71%	-2,028.04%	-4,108.91%	-5,588.98%	-15,973.46%	-6,528.13%	-2,699.00%	-4,984.37%	-5,897.21%	-5,901.60%	-8,221.89%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.01	0.02	0.02	0.04	0.04	0.03	0.04	0.01	0.01	0.02	0.01
Accounts Receivable Turnover	7.83	7.85	4.93	6.96	3.78	1.71	5.27	4.71	9.08	4.63	4.22
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	0.35	0.50	0.55	1.08	1.16	0.70	1.89	1.26	0.65	1.76	1.67
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	46.62	46.52	74.07	52.47	96.47	213.35	69.30	77.46	40.19	78.88	86.52
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	46.62	46.52	74.07	52.47	96.47	213.35	69.30	77.46	40.19	78.88	86.52
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	11	0.22	76	97	30	30	15	11	21	5.57	22
Invested Capital Turnover	0.26	1.01	0.18	0.15	0.15	0.12	0.33	0.36	0.15	0.51	0.51
Increase / (Decrease) in Invested Capital	-6.20	-10	75	21	-67	-0.40	-15	-3.71	10	-16	16
Enterprise Value (EV)	1,434	1,257	169	247	-60	-28	499	1,395	1,794	1,451	951
Market Capitalization	1,635	1,547	358	386	34	36	693	1,803	2,099	1,874	1,677
Book Value per Share	$2.36	$2.94	$2.62	$1.74	$0.72	$5.83	$5.29	$8.99	$6.93	$9.08	$11.26
Tangible Book Value per Share	$2.02	$2.64	$0.92	$0.57	$0.44	$2.81	$4.52	$8.41	$6.35	$8.51	$10.85
Total Capital	212	290	265	236	124	94	209	419	326	429	747
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-201	-290	-190	-139	-94	-64	-194	-408	-305	-424	-725
Capital Expenditures (CapEx)	1.93	4.88	2.75	1.79	0.47	0.71	1.50	1.22	1.76	1.82	1.92
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-21	-25	-29	-22	-7.55	-9.33	-11	-14	-5.87	-23	-18
Debt-free Net Working Capital (DFNWC)	180	265	160	117	86	55	184	394	299	401	708
Net Working Capital (NWC)	180	265	160	117	86	55	184	394	299	401	708
Net Nonoperating Expense (NNE)	32	37	35	7.96	42	12	15	21	32	33	21
Net Nonoperating Obligations (NNO)	-201	-290	-190	-139	-94	-64	-194	-408	-305	-424	-725
Total Depreciation and Amortization (D&A)	3.57	4.65	6.66	5.60	2.75	3.72	3.20	-0.14	3.74	-3.21	-13
Debt-free, Cash-free Net Working Capital to Revenue	-573.03%	-459.73%	-433.69%	-175.84%	-79.10%	-261.07%	-145.39%	-299.70%	-249.00%	-334.59%	-251.04%
Debt-free Net Working Capital to Revenue	5,033.30%	4,830.22%	2,362.89%	918.31%	906.66%	1,540.86%	2,475.56%	8,477.98%	12,689.14%	5,819.67%	10,080.60%
Net Working Capital to Revenue	5,033.30%	4,830.22%	2,362.89%	918.31%	906.66%	1,540.86%	2,475.56%	8,477.98%	12,689.14%	5,819.67%	10,080.60%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($19.80)	($19.65)	($19.05)	($10.80)	($14.48)	($3.51)	($2.02)	($1.64)	($2.40)	($2.92)	($2.45)
Adjusted Weighted Average Basic Shares Outstanding	5.97M	6.58M	8.21M	9.40M	12.44M	17.57M	39.61M	42.87M	46.89M	48.45M	64.40M
Adjusted Diluted Earnings per Share	($19.80)	($19.65)	($19.05)	($10.80)	($14.48)	($3.51)	($2.02)	($1.64)	($2.40)	($2.92)	($2.45)
Adjusted Weighted Average Diluted Shares Outstanding	5.97M	6.58M	8.21M	9.40M	12.44M	17.57M	39.61M	42.87M	46.89M	48.45M	64.40M
Adjusted Basic & Diluted Earnings per Share	($19.80)	($19.65)	($19.05)	($10.80)	($14.48)	($3.51)	($2.02)	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	5.96M	6.47M	6.77M	8.57M	10.44M	14.51M	29.64M	46.74M	47.21M	55.90M	66.38M
Normalized Net Operating Profit after Tax (NOPAT)	-86	-91	-93	-76	-33	-37	-32	-47	-70	-99	-137
Normalized NOPAT Margin	-2,389.88%	-1,654.72%	-1,371.08%	-596.16%	-343.34%	-1,042.87%	-427.98%	-1,019.57%	-2,976.83%	-1,444.56%	-1,945.22%
Pre Tax Income Margin	-3,292.81%	-2,321.11%	-1,894.05%	-920.61%	-1,593.09%	-1,423.96%	-821.61%	-1,520.92%	-4,765.59%	-2,054.76%	-2,248.76%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Celldex Therapeutics' official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	166.01%	384.38%	455.75%	64.42%	272.73%	156.11%	-83.87%	832.09%	110.35%	-71.56%	345.51%
EBITDA Growth	-15.71%	-43.22%	-52.26%	4.30%	-56.11%	-76.85%	-30.74%	-49.54%	-32.24%	-19.42%	-48.66%
EBIT Growth	-33.00%	-37.09%	-39.62%	8.77%	-48.90%	-70.80%	-25.06%	-39.49%	-26.40%	-17.64%	-54.50%
NOPAT Growth	-33.00%	-37.09%	-39.62%	8.77%	-48.90%	-70.80%	-25.06%	-39.49%	-26.40%	-17.64%	-54.50%
Net Income Growth	-30.96%	-31.46%	-27.38%	15.28%	-42.85%	-63.50%	-11.74%	-17.51%	-10.09%	-8.74%	-63.97%
EPS Growth	-26.67%	-32.56%	-26.53%	15.58%	-42.11%	-47.37%	9.68%	16.92%	20.99%	15.48%	-44.64%
Operating Cash Flow Growth	-114.95%	-49.85%	-16.45%	-22.26%	46.03%	-49.49%	-42.25%	-7.84%	-191.35%	0.18%	-33.80%
Free Cash Flow Firm Growth	-1,370.36%	-180.61%	-86.04%	-156.69%	33.98%	40.23%	36.03%	52.46%	-200.81%	-213.53%	-212.32%
Invested Capital Growth	61.09%	89.31%	38.11%	200.15%	-48.19%	-73.78%	-39.36%	-54.34%	163.03%	289.81%	101.06%
Revenue Q/Q Growth	149.69%	296.31%	-40.05%	-72.29%	466.04%	172.31%	-96.22%	1,501.28%	27.74%	-63.18%	-40.85%
EBITDA Q/Q Growth	23.21%	-2.84%	-18.99%	-1.84%	-25.26%	-16.50%	12.03%	-16.49%	-10.77%	-5.21%	-9.51%
EBIT Q/Q Growth	23.90%	-0.68%	-16.45%	-2.26%	-24.20%	-15.49%	14.74%	-14.06%	-12.54%	-7.48%	-11.98%
NOPAT Q/Q Growth	23.90%	-0.68%	-16.45%	-2.26%	-24.20%	-15.49%	14.74%	-14.06%	-12.54%	-7.48%	-11.98%
Net Income Q/Q Growth	25.61%	1.11%	-10.85%	-3.89%	-25.43%	-13.19%	24.24%	-9.25%	-17.52%	-11.80%	-14.24%
EPS Q/Q Growth	25.97%	0.00%	-8.77%	-4.84%	-24.62%	-3.70%	33.33%	3.57%	-18.52%	-10.94%	-14.08%
Operating Cash Flow Q/Q Growth	-58.21%	38.16%	-31.28%	4.81%	30.16%	-71.29%	-24.91%	27.83%	-88.69%	41.31%	-67.42%
Free Cash Flow Firm Q/Q Growth	-78.67%	-6.63%	0.32%	-35.17%	54.05%	3.46%	-6.68%	-0.45%	-190.77%	-0.63%	-6.27%
Invested Capital Q/Q Growth	165.16%	-3.16%	14.59%	2.00%	-54.23%	-50.99%	164.97%	-23.19%	163.67%	-27.36%	36.67%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
EBITDA Margin	-6,625.80%	-1,719.40%	-3,412.72%	-12,540.67%	-2,775.15%	-1,187.29%	-27,657.69%	-2,012.01%	-1,744.69%	-4,984.77%	-9,228.63%
Operating Margin	-6,804.91%	-1,728.77%	-3,357.91%	-12,389.93%	-2,718.46%	-1,152.92%	-26,030.77%	-1,854.16%	-1,633.53%	-4,768.26%	-9,027.19%
EBIT Margin	-6,804.91%	-1,728.77%	-3,357.91%	-12,389.93%	-2,718.46%	-1,152.92%	-26,030.77%	-1,854.16%	-1,633.53%	-4,768.26%	-9,027.19%
Profit (Net Income) Margin	-6,580.84%	-1,642.10%	-3,036.30%	-11,381.34%	-2,522.08%	-1,048.32%	-21,030.77%	-1,434.83%	-1,319.99%	-4,007.83%	-7,740.43%
Tax Burden Percent	100.00%	30.96%	0.00%	0.00%	0.00%	30.62%	100.00%	0.00%	0.00%	29.83%	100.00%
Interest Burden Percent	96.71%	306.76%	0.00%	0.00%	0.00%	296.95%	80.79%	0.00%	0.00%	281.76%	85.75%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-288.47%	-175.64%	-352.70%	-1,704.94%	-498.65%	-414.16%	-5,656.50%	-595.62%	-552.73%	-1,716.76%	-2,148.84%
ROIC Less NNEP Spread (ROIC-NNEP)	-286.49%	-173.69%	-350.69%	-1,702.56%	-495.29%	-411.42%	-5,655.71%	-594.97%	-551.60%	-1,715.39%	-2,147.53%
Return on Net Nonoperating Assets (RNNOA)	273.46%	166.13%	329.68%	1,614.82%	467.42%	396.81%	5,461.86%	575.24%	529.55%	1,675.58%	2,085.59%
Return on Equity (ROE)	-15.01%	-9.52%	-23.02%	-90.12%	-31.23%	-17.35%	-194.65%	-20.38%	-23.18%	-41.18%	-63.25%
Cash Return on Invested Capital (CROIC)	-470.67%	-558.47%	-446.98%	-612.66%	-502.99%	-689.66%	-533.18%	-605.58%	-722.99%	-1,118.85%	-751.15%
Operating Return on Assets (OROA)	-17.67%	-10.22%	-28.26%	-114.85%	-36.54%	-19.39%	-264.90%	-26.89%	-29.54%	-53.22%	-84.85%
Return on Assets (ROA)	-17.09%	-9.71%	-25.55%	-105.50%	-33.90%	-17.63%	-214.01%	-20.81%	-23.87%	-44.73%	-72.76%
Return on Common Equity (ROCE)	-15.01%	-9.52%	-23.02%	-90.12%	-31.23%	-17.35%	-194.65%	-20.38%	-23.18%	-41.18%	-63.25%
Return on Equity Simple (ROE_SIMPLE)	-30.68%	0.00%	-39.19%	-40.76%	-50.51%	0.00%	-17.28%	-18.46%	-19.61%	0.00%	-25.44%
Net Operating Profit after Tax (NOPAT)	-19	-20	-23	-23	-29	-33	-28	-32	-36	-39	-44
NOPAT Margin	-4,763.44%	-1,210.14%	-2,350.54%	-8,672.95%	-1,902.92%	-807.04%	-18,221.54%	-1,297.91%	-1,143.47%	-3,337.78%	-6,319.04%
Net Nonoperating Expense Percent (NNEP)	-1.98%	-1.95%	-2.01%	-2.38%	-3.36%	-2.74%	-0.80%	-0.65%	-1.14%	-1.37%	-1.32%
Return On Investment Capital (ROIC_SIMPLE)	-	-5.98%	-	-	-	-7.77%	-3.39%	-	-	-5.25%	-6.25%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	1,604.67%	409.11%	686.66%	2,694.40%	541.92%	213.80%	5,835.26%	365.41%	315.07%	873.45%	1,556.83%
R&D to Revenue	5,300.25%	1,419.65%	2,771.25%	9,795.52%	2,276.53%	736.53%	20,295.51%	1,588.75%	1,418.46%	3,994.81%	7,570.36%
Operating Expenses to Revenue	6,904.91%	1,828.77%	3,457.91%	12,489.93%	2,818.46%	1,252.92%	26,130.77%	1,954.16%	1,733.53%	4,868.26%	9,127.19%
Earnings before Interest and Taxes (EBIT)	-28	-28	-32	-33	-41	-48	-41	-46	-52	-56	-63
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-27	-28	-33	-34	-42	-49	-43	-50	-56	-59	-64
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	3.81	6.44	5.61	5.78	5.27	4.37	2.37	3.00	2.87	2.24	1.71
Price to Tangible Book Value (P/TBV)	4.13	7.02	6.16	6.40	5.92	4.66	2.44	3.10	2.97	2.33	1.78
Price to Revenue (P/Rev)	1,220.77	890.64	539.21	492.56	297.97	272.34	326.69	293.83	225.85	238.82	159.39
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	45.17	84.43	58.31	54.37	93.69	260.34	78.54	144.33	50.06	43.79	17.90
Enterprise Value to Revenue (EV/Rev)	920.43	761.26	450.83	414.92	244.05	210.79	191.01	197.19	150.07	135.50	70.32
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-0.95	-0.96	-0.94	-0.95	-0.94	-0.96	-0.97	-0.97	-0.96	-0.98	-0.97
Leverage Ratio	1.06	1.07	1.07	1.09	1.10	1.08	1.05	1.05	1.07	1.07	1.04
Compound Leverage Factor	1.03	3.28	0.00	0.00	0.00	3.22	0.84	0.00	0.00	3.01	0.89
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	29.26	43.25	41.94	38.67	16.97	27.36	38.03	44.36	34.60	20.29	17.57
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	20.54	17.07	19.03	16.93	8.84	13.87	31.77	29.36	24.27	18.91	21.67
Quick Ratio	19.87	16.41	18.38	16.16	8.46	13.69	31.44	29.06	23.58	18.38	21.06
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-28	-30	-29	-40	-18	-18	-19	-19	-55	-55	-59
Operating Cash Flow to CapEx	-10,200.58%	-9,260.43%	-4,883.59%	-6,633.17%	-12,097.45%	-4,884.83%	-11,813.37%	-10,703.28%	-10,153.58%	-4,295.77%	-20,517.74%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.00	0.01	0.01	0.01	0.01	0.02	0.01	0.01	0.02	0.01	0.01
Accounts Receivable Turnover	5.58	9.08	4.05	30.28	19.80	4.63	3.05	10.05	18.07	4.22	4.05
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	0.30	0.65	0.84	0.85	1.10	1.76	1.51	2.13	2.38	1.67	1.75
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	65.41	40.19	90.21	12.05	18.44	78.88	119.77	36.32	20.20	86.52	90.18
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	65.41	40.19	90.21	12.05	18.44	78.88	119.77	36.32	20.20	86.52	90.18
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	22	21	24	25	11	5.57	15	11	30	22	30
Invested Capital Turnover	0.06	0.15	0.15	0.20	0.26	0.51	0.31	0.46	0.48	0.51	0.34
Increase / (Decrease) in Invested Capital	8.32	10	6.72	17	-11	-16	-9.59	-13	19	16	15
Enterprise Value (EV)	991	1,794	1,420	1,351	1,065	1,451	1,160	1,637	1,497	951	532
Market Capitalization	1,315	2,099	1,699	1,603	1,301	1,874	1,984	2,439	2,253	1,677	1,205
Book Value per Share	$7.39	$6.93	$6.41	$5.87	$5.22	$9.08	$14.24	$12.34	$11.86	$11.26	$10.59
Tangible Book Value per Share	$6.80	$6.35	$5.84	$5.30	$4.65	$8.51	$13.78	$11.93	$11.45	$10.85	$10.18
Total Capital	345	326	303	278	247	429	839	814	786	747	703
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-323	-305	-278	-253	-235	-424	-824	-802	-756	-725	-673
Capital Expenditures (CapEx)	0.35	0.24	0.59	0.41	0.16	0.67	0.34	0.27	0.55	0.76	0.27
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-5.16	-5.87	-4.01	-3.52	-17	-23	-15	-18	-9.25	-18	-12
Debt-free Net Working Capital (DFNWC)	318	299	274	249	218	401	809	784	747	708	662
Net Working Capital (NWC)	318	299	274	249	218	401	809	784	747	708	662
Net Nonoperating Expense (NNE)	7.40	6.97	6.63	7.26	9.39	9.97	4.38	3.42	5.63	7.87	9.88
Net Nonoperating Obligations (NNO)	-323	-305	-278	-253	-235	-424	-824	-802	-756	-725	-673
Total Depreciation and Amortization (D&A)	0.73	0.15	-0.53	-0.40	-0.86	-1.42	-2.54	-3.94	-3.55	-2.54	-1.40
Debt-free, Cash-free Net Working Capital to Revenue	-479.02%	-249.00%	-127.27%	-108.23%	-395.21%	-334.59%	-243.96%	-216.82%	-92.72%	-251.04%	-152.82%
Debt-free Net Working Capital to Revenue	29,555.43%	12,689.14%	8,710.41%	7,655.12%	4,996.49%	5,819.67%	13,324.00%	9,447.33%	7,485.46%	10,080.60%	8,754.32%
Net Working Capital to Revenue	29,555.43%	12,689.14%	8,710.41%	7,655.12%	4,996.49%	5,819.67%	13,324.00%	9,447.33%	7,485.46%	10,080.60%	8,754.32%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.57)	($0.57)	($0.62)	($0.65)	($0.81)	($0.84)	($0.56)	($0.54)	($0.64)	($0.71)	($0.81)
Adjusted Weighted Average Basic Shares Outstanding	46.92M	46.89M	47.21M	47.25M	47.26M	48.45M	58.87M	66.02M	66.29M	64.40M	66.38M
Adjusted Diluted Earnings per Share	($0.57)	($0.57)	($0.62)	($0.65)	($0.81)	($0.84)	($0.56)	($0.54)	($0.64)	($0.71)	($0.81)
Adjusted Weighted Average Diluted Shares Outstanding	46.92M	46.89M	47.21M	47.25M	47.26M	48.45M	58.87M	66.02M	66.29M	64.40M	66.38M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	47.10M	47.21M	47.25M	47.26M	47.26M	55.90M	65.91M	66.29M	66.34M	66.38M	66.39M
Normalized Net Operating Profit after Tax (NOPAT)	-19	-20	-23	-23	-29	-33	-28	-32	-36	-39	-44
Normalized NOPAT Margin	-4,763.44%	-1,210.14%	-2,350.54%	-8,672.95%	-1,902.92%	-807.04%	-18,221.54%	-1,297.91%	-1,143.47%	-3,337.78%	-6,319.04%
Pre Tax Income Margin	-6,580.84%	-5,303.22%	0.00%	0.00%	0.00%	-3,423.60%	-21,030.77%	0.00%	0.00%	-13,435.15%	-7,740.43%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Key Financial Trends

Celldex Therapeutics (NASDAQ: CLDX) continues to operate with significant losses across recent quarters, reflecting ongoing heavy investments in research and development. Notably, the company reported a consolidated net loss of $53.8 million in Q1 2025, widening from $47.1 million in Q4 2024 and $42.1 million in Q3 2024. The losses are driven by substantial R&D and operating expenses that consistently exceed their limited revenue.

Financial trends over the past four years reveal some key points:

Cash and short-term investments remain robust, with $671 million in combined cash and short-term investments as of Q1 2025, providing a strong liquidity position to fund operations.
Interest and investment income have steadily contributed around $8-10 million per quarter, partially offsetting operating losses.
Total assets have increased over time, reaching approximately $739 million at Q1 2025, signaling growth in resource base.
Total equity has remained stable around $700-800 million, suggesting controlled dilution or equity financing.

Operating revenue is minimal, around $0.7 million in Q1 2025, down from a peak of about $4.1 million in Q4 2023, indicating limited commercial sales.
Shares outstanding have increased modestly to around 66.4 million in Q1 2025 from approximately 49 million in 2022, reflecting dilution likely due to equity raises.
Diluted earnings per share are deeply negative, around -$0.81 in Q1 2025, moving slightly from -$0.71 in Q4 2024, consistent with the net loss trend.
Capital expenditures remain relatively low, under $1 million quarterly, indicating limited investment in fixed assets.

Operating expenses, driven primarily by R&D ($52.6 million in Q1 2025) and SG&A expenses ($10.8 million in Q1 2025), significantly exceed revenue, causing large operating losses.
Net cash from operating activities continues to be negative, with a $54.4 million outflow in Q1 2025, consistent with ongoing cash burn from operations.
Net income/loss for all quarters remains negative, showing no recent profitability, with cumulative losses increasing each quarter.
Total liabilities have increased slightly but remain well below total assets, though the company carries some accrued expenses and current liabilities around $32 million.

In summary, Celldex Therapeutics remains focused on development-stage operations, which is reflected in its persistent net losses, heavy spending on research and development, and limited revenues. However, the company maintains a strong liquidity position with substantial cash and investments and steady interest income, enabling it to continue funding operations as it advances clinical programs. Investors should consider the ongoing cash burn and lack of profitability while noting the robust cash reserves as a buffer in the near term.

08/30/25 09:02 AM ETAI Generated. May Contain Errors.

Financials Breakdown Chart

Frequently Asked Questions About Celldex Therapeutics' Financials

When does Celldex Therapeutics' fiscal year end?

According to the most recent income statement we have on file, Celldex Therapeutics' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Celldex Therapeutics' net income changed over the last 10 years?

Celldex Therapeutics' net income were at -$157.86 million at the end of 2024, a 11.6% increase from 2023, and a 33.7% increase since 2014. See Celldex Therapeutics' forecast for analyst expectations on what’s next for the company.

What is Celldex Therapeutics' operating income?

Celldex Therapeutics' total operating income in 2024 was -$195.08 million, based on the following breakdown:

Total Gross Profit: $7.02 million
Total Operating Expenses: $202.10 million

How has Celldex Therapeutics' revenue changed over the last 10 years?

Over the last 10 years, Celldex Therapeutics' total revenue changed from $3.59 million in 2014 to $7.02 million in 2024, a change of 95.8%.

How much debt does Celldex Therapeutics have?

Celldex Therapeutics' total liabilities were at $45.34 million at the end of 2024, a 24.4% increase from 2023, and a 24.7% increase since 2014.

How much cash does Celldex Therapeutics have?

In the past 10 years, Celldex Therapeutics' cash and equivalents has ranged from $11.23 million in 2019 to $72.11 million in 2015, and is currently $28.36 million as of their latest financial filing in 2024.

How has Celldex Therapeutics' book value per share changed over the last 10 years?

Over the last 10 years, Celldex Therapeutics' book value per share changed from 2.36 in 2014 to 11.26 in 2024, a change of 376.6%.

Related Companies

This page (NASDAQ:CLDX) was last updated on 8/30/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Celldex Therapeutics (CLDX) Financials

Key Financial Trends

Financials Breakdown Chart

Frequently Asked Questions About Celldex Therapeutics' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Celldex Therapeutics (CLDX) Financials

Annual Income Statements for Celldex Therapeutics

Quarterly Income Statements for Celldex Therapeutics

Annual Cash Flow Statements for Celldex Therapeutics

Quarterly Cash Flow Statements for Celldex Therapeutics

Annual Balance Sheets for Celldex Therapeutics

Quarterly Balance Sheets for Celldex Therapeutics

Annual Metrics And Ratios for Celldex Therapeutics

Quarterly Metrics And Ratios for Celldex Therapeutics

Key Financial Trends

Financials Breakdown Chart

Frequently Asked Questions About Celldex Therapeutics' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools